Riddhi Siddhi Gluco Biols Limited (524480) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Riddhi Siddhi Gluco Biols Limited ₹332, price ₹745, upside -55.4%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Riddhi Siddhi Gluco Biols Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹242.34 – ₹825.90 · fair‑value band ₹230.77 – ₹499.72 · the ₹745.15 price screens above the ₹332.34 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Riddhi Siddhi Gluco Biols in your weekly email
Every Wednesday you see whether Riddhi Siddhi Gluco Biols is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Riddhi Siddhi Gluco Biols Limited, together with its subsidiaries, engages in the trading of agriculture and metal commodities primarily in India. It operates through Trading Business, Wind Energy Generation, Paper Reprocessing, and Real Estate Business segments.
Show more
Riddhi Siddhi Gluco Biols Limited, together with its subsidiaries, engages in the trading of agriculture and metal commodities primarily in India. It operates through Trading Business, Wind Energy Generation, Paper Reprocessing, and Real Estate Business segments. The company also generates and sells wind power; and manufactures and sells newsprint, writing, and printing papers. As of March 31, 2020, it operated windmills with a total capacity of 33.15 MW in Tamilnadu, Maharashtra, and Gujarat. The company was founded in 1990 and is based in Ahmedabad, India.
Stock analysis
Riddhi Siddhi Gluco Biols Limited (524480) currently trades at ₹745.15, while our model-based Fair Value estimate is ₹332.34, implying the stock looks roughly 124.2% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹1,418 per share, and 1 of the 4 models we run sit above the ₹745.15 price.
Bear case: the DCF Models group reads lowest at ₹224.52, and 3 of the 4 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹230.77 (bear) to ₹499.72 (bull), the price of ₹745.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Consumer Goods sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Riddhi Siddhi Gluco Biols Limited reported revenue of ₹2.4B in FY2026 versus ₹2.2B in FY2022, a compound +1.4%/yr. Reported net income was −₹44.8M in FY2026.
Key figures
Market cap ₹1.7B (≈ $17.3M) · P/E ratio 20.2 · P/S ratio 0.30 · EPS (TTM) ₹11.95 · Dividend yield 0.3% · Net margin −1.9% · Return on equity −0.3% · Return on assets (EBIT) −0.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 81% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Goods peers we cover trades at 10% fair-value upside, at −55%, 524480 screens richer than that median.
Fair Value models
Bear ₹230.77Fair Value ₹332.34Bull ₹499.72
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹4.85 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.12/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+74.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.9%
Start year 2021 (pandemic). Over 10 years: −3.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.8%
’14
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.3% (2021) → −8.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Riddhi Siddhi Gluco Biols Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 296 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−55% · Bottom 25%
Profitability
Return on assets0% · Bottom 25%
Net margin (TTM)2% · Below median
Operating margin (TTM)−3% · Bottom 25%
Growth and dividend
Revenue growth41% · Top 25%
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.11× · Below median
Valuation Multiplesvs Farm Products median · lower = cheaper
P/E (TTM)20.2× · Pricier than median
P/B0.11× · Cheapest 25%
P/S (TTM)0.30× · Cheaper than median
EV/EBITDA7.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 26
FUTURE (revenue growth)100· sector 21
PAST (return on equity)0· sector 19
HEALTH (low debt)94· sector 94
DIVIDEND (yield)5· sector 47
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Riddhi Siddhi Gluco Biols Limited (524480) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹332.34 versus a price of ₹745.15, about −55% upside (overvalued).
What is the fair value of 524480?
Our model-based fair value for Riddhi Siddhi Gluco Biols Limited is ₹332.34 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹745.15.
What is the quality score of 524480?
Riddhi Siddhi Gluco Biols Limited has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Riddhi Siddhi Gluco Biols Limited (524480)?
Our model-based price target is the fair value of ₹332.34 (as of Sep 24, 2026) from 4 valuation models. Cautious scenario ₹230.77, optimistic scenario ₹499.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Riddhi Siddhi Gluco Biols Limited stock forecast for 2026?
Our models put fair value at ₹332.34, about −55% upside versus a price of ₹745.15 (overvalued). Cautious scenario ₹230.77, optimistic scenario ₹499.72. The calculation is refreshed regularly with new filings.
What is the revenue of Riddhi Siddhi Gluco Biols Limited (524480)?
Riddhi Siddhi Gluco Biols Limited reported trailing-twelve-month revenue of about ₹5.5B (latest available figure, as of Sep 24, 2026).
Does Riddhi Siddhi Gluco Biols Limited pay a dividend?
Riddhi Siddhi Gluco Biols Limited currently shows a dividend yield of about 0.27% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Riddhi Siddhi Gluco Biols Limited (524480)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Riddhi Siddhi Gluco Biols Limited it is ₹332.34 per share (as of Sep 24, 2026), against a price of ₹745.15. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Riddhi Siddhi Gluco Biols Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 524480 trades above its calculated fair value: price ₹745.15, fair value ₹332.34, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 524480?
No. The price is what the market pays today (₹745.15); the fair value is what the company's own numbers justify (₹332.34). For Riddhi Siddhi Gluco Biols Limited the two are ₹412.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Riddhi Siddhi Gluco Biols Limited worth?
The market values Riddhi Siddhi Gluco Biols Limited at about ₹1.7B (market capitalisation, as of Sep 24, 2026). Per share that is ₹745.15; our models calculate a fair value of ₹332.34 per share.
What do the bullish and bearish scenarios say about 524480?
Our models span a range for Riddhi Siddhi Gluco Biols Limited: cautious scenario ₹230.77, base ₹332.34, optimistic ₹499.72 per share (as of Sep 24, 2026, price ₹745.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 524480?
Riddhi Siddhi Gluco Biols Limited trades at a price-to-earnings ratio of 20.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹332.34 is built from several models across several years. Other multiples: P/B 0.1, P/S 0.3, EV/EBITDA 7.4.
How solid is the balance sheet of Riddhi Siddhi Gluco Biols Limited (524480)?
Balance-sheet figures for Riddhi Siddhi Gluco Biols Limited (as of Sep 24, 2026): return on equity −0.3%, debt of 0.11 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 524480 from its 52-week high?
Riddhi Siddhi Gluco Biols Limited trades at ₹745.15, about 10% below its 52-week high of ₹825.90 and 81% above the low of ₹411.20 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ₹332.34 is for.
Which stocks are comparable to Riddhi Siddhi Gluco Biols Limited?
From the same area (Consumer Goods) we also value Archer-Daniels-Midland Company, Muyuan Foods Group, Bunge Global SA, Tyson Foods, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Riddhi Siddhi Gluco Biols Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹745.15, calculated fair value ₹332.34 (−55%), Quality Score 51/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 524480 calculated?
We run Riddhi Siddhi Gluco Biols Limited through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹332.34, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Riddhi Siddhi Gluco Biols Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Riddhi Siddhi Gluco Biols Limited (524480)?
The closing price on Sep 24, 2026 was ₹745.15. Our model-based fair value is ₹332.34, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Riddhi Siddhi Gluco Biols Limited right now?
The price sits above even our optimistic bull case (₹499.72). The favourable scenario is already priced in. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹230.77 to ₹499.72) leaves room in how you read the outcome.
Key figures of Riddhi Siddhi Gluco Biols Limited
How large is the market capitalisation of Riddhi Siddhi Gluco Biols Limited (524480)?
The market capitalisation of Riddhi Siddhi Gluco Biols Limited is ₹1.7B (≈ $17.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Riddhi Siddhi Gluco Biols Limited (524480)?
The price-to-sales ratio of Riddhi Siddhi Gluco Biols Limited is 0.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Riddhi Siddhi Gluco Biols Limited (524480)?
Earnings per share at Riddhi Siddhi Gluco Biols Limited are ₹11.95 (price ÷ EPS = P/E 20.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Riddhi Siddhi Gluco Biols Limited (524480)?
The dividend yield of Riddhi Siddhi Gluco Biols Limited is 0.3% (payout 16.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Riddhi Siddhi Gluco Biols Limited (524480)?
The net margin of Riddhi Siddhi Gluco Biols Limited is −1.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Riddhi Siddhi Gluco Biols Limited (524480)?
The return on equity (ROE) of Riddhi Siddhi Gluco Biols Limited is −0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Riddhi Siddhi Gluco Biols Limited (524480)?
On an EBIT basis the return on assets of Riddhi Siddhi Gluco Biols Limited is −0.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Riddhi Siddhi Gluco Biols Limited (524480)?
The operating margin of Riddhi Siddhi Gluco Biols Limited is −2.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Riddhi Siddhi Gluco Biols Limited (524480)?
Revenue at Riddhi Siddhi Gluco Biols Limited is growing +40.7% versus a year earlier (3y avg +10.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Riddhi Siddhi Gluco Biols Limited (524480) generate?
The free cash flow of Riddhi Siddhi Gluco Biols Limited is −₹95.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Riddhi Siddhi Gluco Biols Limited (524480) carry?
The net debt of Riddhi Siddhi Gluco Biols Limited is ₹1.7B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Riddhi Siddhi Gluco Biols Limited in the live analysis
One click puts Riddhi Siddhi Gluco Biols Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
